CIGB 845

Drug Profile

CIGB 845

Alternative Names: CIGB845

Latest Information Update: 30 Aug 2016

Price : $50

At a glance

  • Originator Center for Genetic Engineering and Biotechnology
  • Class Peptides; Recombinant proteins
  • Mechanism of Action Growth hormone releasing factor agonists; Myelin protein stimulants; Neurogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neurological disorders

Most Recent Events

  • 30 Aug 2016 The Centre for Genetic Engineering and Biotechnology plans to initiate phase I trial in Cerebral infarction in Cuba (RPCEC00000214)
  • 01 Jan 2013 Preclinical trials in Neurological disorders in Cuba (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top